The New Pain Drug Is Just Tylenol Plus Advil — and That's the Whole Business Story

The press release calls Combogesic a new non-opioid pain medication coming to the U.S. Read the label and the novelty thins out fast: it's a single tablet of acetaminophen plus ibuprofen. Tylenol and Advil, in the amounts a patient would take anyway, pressed into one pill. Americans have been stacking those two by hand from the drugstore shelf for decades. The chemistry is not the story. The story is that this combination existed, FDA-approved, for three and a half years before anyone found a way to sell it in America.

Each Combogesic tablet holds 325 milligrams of acetaminophen and 97.5 milligrams of ibuprofen. AFT Pharmaceuticals wraps them in a fast-dissolving QikSolv formulation so a patient gets one prescription instead of coordinating two bottles and two dosing schedules. The combination is genuinely useful — the two work by different pathways and the single-tablet form removes the compliance problem that mild acute pain usually exposes. By now Combogesic, sold as Maxigesic elsewhere, is available in 66 countries. This is not a startup discovering a molecule. This is a mature product from a New Zealand drugmaker finally landing in the world's largest pain market.

So the obvious question is why it took so long. FDA approval came in March 2023. The U.S. launch happened this month, through Mark Cuban's Cost Plus Marketplace. Three and a half years is not a delay in chemistry. It is a delay in finding a channel that a drug like this can survive in.

Here is the real problem. Both ingredients are off-patent and sold over the counter. A bottle of ibuprofen at Cost Plus runs a few dollars. In the U.S. prescription market, money is usually made by pricing a drug above its cost and then negotiating rebates with insurers and pharmacy benefit managers. That machinery needs a premium to move around. A branded pill assembled from two cheap generics has nothing to trade there. The inconvenience it saves — grabbing two bottles, timing two doses — is real but small, and nobody in the middle makes enough on it to push it through the normal channel. AFT spent years hunting for a U.S. distributor for the tablet and kept bouncing off the same wall.

Mark Cuban's marketplace is built differently. Cost Plus charges a stated markup over manufacturing cost, prices by weight, sells for cash, and skips the insurer middlemen. For a product whose components cost pennies, that model fits the way no rebate-driven pharmacy chain can. There is no premium to defend, so you can just make the medicine reachable at a transparent price and let it be cheap. The non-opioid moment gives the product its timing: doctors and regulators are actively steering acute-pain patients away from opioids, and Combogesic is a script that points the same direction without a controlled substance.

Keep the size of this in proportion. AFT is not a one-drug company. In fiscal 2026 it reported revenue of NZ$254.7 million, up 22%, a record operating profit of NZ$24.4 million, and now targets NZ$300 million in the year ahead. The U.S. launch is a long option on those numbers, not a line on them yet — no script volume, no pricing terms for the deal, nothing quantified. Note also where the stock actually lives. Combogesic's gains accrue to a company listed in New Zealand and Australia (AFT.NZ, AFP.AX), not on a U.S. exchange, with a market value around NZ$458 million. For a U.S. investor this is a watch item or an overseas access decision, not a ticker in the usual app.

The whole bet reduces to one falsifiable test. A patient seeking non-opioid relief can buy acetaminophen and ibuprofen for a few dollars without a doctor visit. The combination tablet only wins if enough people decide the single prescription is worth the hurdle of the doctor's appointment and the script. The Cost Plus launch is the cleanest way yet to run that test at scale, because the price is transparent and the economics cannot hide behind rebates. Watch whether U.S. scripts for Combogesic actually get written and filled — that is use, and it will show up on AFT's income statement or it won't. The announcement changes nothing about the patient's easy alternative. I suspect the real question is whether a convenience product this small can clear that bar, and that is a question to reask in a year, not to settle on the news.